CONMED Corporation 2012 Form 10-K Summary
Business context and reporting period
CONMED is a medical technology company focused on surgical devices and equipment for minimally invasive procedures and monitoring across orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The filing covers the fiscal year ended December 31, 2012; the requested “2012 Q4” data is included only as part of the annual filing and selected quarterly information.
The company had approximately 3,600 employees and sold products in more than 100 countries. Approximately 50% of 2012 sales were to customers outside the United States, approximately 80% were from disposable products, and approximately 90% related to surgical products.
Financial performance and key metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Net sales | $767.1 million | $725.1 million | Up 5.8% |
| Gross profit | $405.8 million | $374.9 million | Up 8.2% |
| Gross margin | 52.9% | 51.7% | Up 1.2 percentage points |
| Income from operations | $65.2 million | $8.3 million | Improved materially |
| Operating margin | 8.5% | 1.1% | Up 7.4 percentage points |
| Net income | $40.5 million | $0.8 million | Improved materially |
| Diluted EPS | $1.41 | $0.03 | Improved materially |
| Operating cash flow | $95.2 million | $103.0 million | Down $7.8 million |
| Capital expenditures | $21.5 million | $17.6 million | Up $4.0 million |
2012 net sales growth was driven primarily by arthroscopy and the Musculoskeletal Transplant Foundation (MTF) agreement. Single-use and reposable product sales increased 8.5% to $613.5 million, while capital equipment sales decreased 3.9% to $153.6 million.
2012 selling and administrative expense increased to $302.5 million, or 39.4% of sales, from 38.1% in 2011. Research and development expense declined to $28.2 million, or 3.7% of sales. Interest expense declined to $5.7 million from $6.7 million, and the effective tax rate was 31.9%.
Cash and cash equivalents were $23.7 million at year-end, including approximately $19.6 million held by foreign subsidiaries. Net working capital was $223.7 million. Total debt was $161.9 million, including $153.0 million drawn on the revolving credit facility. Available capacity at December 31, 2012 was $87.2 million, with approximately $9.8 million reserved for letters of credit.
Material changes versus the prior comparable period
- Arthroscopy sales increased 14.0% to $330.6 million, primarily from the MTF arrangement and procedure-specific products.
- Powered surgical instrument sales increased 1.4% to $150.0 million.
- Electrosurgery sales decreased 2.9% to $95.7 million, primarily because of lower generator sales.
- Endosurgery sales increased 0.4% to $74.0 million.
- Patient Care sales decreased 3.0% to $63.7 million.
- Endoscopic Technologies sales increased 7.9% to $53.2 million, and its operating margin improved to 5.1% from 0.6%.
- The 2011 results included a $60.3 million goodwill impairment charge for Patient Care; no comparable impairment was recorded in 2012.
- 2012 included $7.1 million of restructuring charges in cost of sales and $6.5 million of administrative consolidation costs in other expense, compared with $3.5 million and $0.8 million, respectively, in 2011.
- CONMED acquired Viking Systems in September 2012 for approximately $22.5 million in cash, recording $22.0 million of goodwill. Viking contributed $3.4 million of 2012 sales and a $1.5 million pretax loss after acquisition.
- The company initiated a quarterly dividend of $0.15 per share in 2012, or $0.60 per share for the year, and repurchased approximately $3.9 million of common stock.
Guidance, outlook, commentary, risks and unusual items
Management stated that cash flow from operations, cash on hand and available borrowing capacity were expected to be adequate for operating needs, debt service, capital expenditures and planned share repurchases. Capital expenditures were expected to approximate $20.0 million in 2013. The company expected approximately $8.0 million to $10.0 million of restructuring costs in 2013 and expected the current restructuring phase to be substantially completed during 2013.
Management expected pension expense of approximately $1.0 million in 2013 and pension contributions of approximately $7.5 million. The company also expected to fund the remaining $84.0 million of contingent MTF payments over four years, including the $34.0 million paid on January 3, 2013.
On January 17, 2013, CONMED entered into an amended and restated $350.0 million revolving credit facility expiring January 17, 2018, replacing the prior $250.0 million facility. The credit agreement is secured by substantially all personal property and assets and contains financial and operating covenants.
- Healthcare cost-containment efforts, GPO and IHN purchasing concentration, competitive pricing and reduced hospital capital spending may pressure revenue and margins.
- Approximately 50% of sales are international, creating foreign currency, geopolitical, regulatory and economic exposure. Foreign exchange movements reduced 2012 sales by approximately $4.4 million and pretax income by approximately $0.8 million versus 2011 rates.
- The 2.3% U.S. medical-device excise tax became effective January 1, 2013. Management estimated the impact at approximately 0.8% to 1.0% of total global sales if not offset through pricing or other actions.
- The MTF arrangement depends on the availability, quality, regulatory acceptance and market adoption of donated allograft tissue. The company accrued $84.0 million of contingent consideration based on its expectation that supply targets would be met.
- Regulatory inspections, product recalls, product liability, patent disputes and changing international medical-device requirements could adversely affect operations. A patent infringement complaint filed by Bonutti Skeletal Innovations in September 2012 remained unresolved, and potential losses could not be estimated.
- Variable-rate debt creates interest-rate exposure; a 1 percentage-point increase in comparable borrowing rates was estimated to reduce pretax income by approximately $1.5 million annually.
The company reported effective disclosure controls and effective internal control over financial reporting as of December 31, 2012. PricewaterhouseCoopers LLP issued an unqualified opinion on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- Whether arthroscopy and MTF-related growth is sustainable after separating underlying volume, pricing, foreign exchange and acquisition effects.
- The effect of the U.S. medical-device excise tax and healthcare purchasing pressures on 2013 gross and operating margins.
- Progress, cash cost and realized savings from the restructuring program, including the projected $8.0 million to $10.0 million of 2013 charges.
- MTF tissue supply performance, contingent payments totaling $84.0 million, and the long-term economics of the 25-year agreement.
- Leverage, covenant compliance, borrowing availability and refinancing terms under the amended $350.0 million credit facility.
- Integration and profitability of Viking Systems, including the preliminary purchase-price allocation and recorded goodwill.
- Potential exposure from the Bonutti patent litigation, regulatory actions, product recalls and product liability claims.
- Patient Care sales and profitability, given its 2012 operating loss of $2.2 million following the prior-year goodwill impairment.